#emcure
Emcure hits the “sweet spot” on weightloss brand Poviztra, says executive
Emcure's Poviztra weight loss brand thrives post-price cut, contributing to $1 billion revenue milestone for FY26.
Emcure doubling down on biosimilars pipeline: MD Satish Mehta
Emcure currently has six biosimilars in the market, launched through its subsidiary Gennova Biopharmaceuticals. While it has developed these in-house so far, the drugmaker will also scout for partners with products not in their pipeline, for commercialisation…